322 related articles for article (PubMed ID: 32133275)
1. Objective response rate assessment in oncology: Current situation and future expectations.
Aykan NF; Özatlı T
World J Clin Oncol; 2020 Feb; 11(2):53-73. PubMed ID: 32133275
[TBL] [Abstract][Full Text] [Related]
2. Imaging biomarkers for evaluating tumor response: RECIST and beyond.
Ko CC; Yeh LR; Kuo YT; Chen JH
Biomark Res; 2021 Jul; 9(1):52. PubMed ID: 34215324
[TBL] [Abstract][Full Text] [Related]
3. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
5. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
6. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
8. Imaging response assessment for oncology: An algorithmic approach.
Ruchalski K; Dewan R; Sai V; McIntosh LJ; Braschi-Amirfarzan M
Eur J Radiol Open; 2022; 9():100426. PubMed ID: 35693043
[TBL] [Abstract][Full Text] [Related]
9. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
[TBL] [Abstract][Full Text] [Related]
10. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
11. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
12. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.
Martins EB; Chojniak R; Kowalski LP; Nicolau UR; Lima EN; Bitencourt AG
PLoS One; 2015; 10(11):e0140009. PubMed ID: 26562784
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
[TBL] [Abstract][Full Text] [Related]
16. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.
Liu Y; Litière S; de Vries EG; Sargent D; Shankar L; Bogaerts J; Seymour L
Eur J Cancer; 2014 Jan; 50(2):260-6. PubMed ID: 24239447
[TBL] [Abstract][Full Text] [Related]
17. Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma.
Arora A; Kumar A
J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S126-9. PubMed ID: 25755604
[TBL] [Abstract][Full Text] [Related]
18. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
[TBL] [Abstract][Full Text] [Related]
19. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
